Despite AKR1B10 being considered a key factor in inducing cancer and acquired drug resistance, its expression characteristics in HCC and its correlation with clinicopathological features and tumor immune microenvironment have not been detailed, and its impact on clinical prognosis in HCC remains controversial16. This evidence concerns the gene AKR1B10 and cancer.